Osteogenesis Imperfecta: Prospects for molecular therapeutics

Molecular Genetics and Metabolism

Volumn 71, Issue 1-2, 2000, Pages 225-232

  Forlino, Antonella ^a   Marini, Joan C ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Brittle mouse; Collagen; Osteogenesis Imperfecta; Ribozymes

Indexed keywords

AMINO ACID; COLLAGEN TYPE 1; GLYCINE; RIBOZYME;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; CELL TRANSPLANTATION; CLINICAL FEATURE; DISEASE CLASSIFICATION; GENE MUTATION; GENE THERAPY; GENETIC VARIABILITY; GENOTYPE; HUMAN; KNOCKOUT MOUSE; MOLECULAR GENETICS; MOUSE; NONHUMAN; OSTEOGENESIS IMPERFECTA; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0033819104     PISSN: 10967192     EISSN: None     Source Type: Journal    
DOI: 10.1006/mgme.2000.3039     Document Type: Article

References (43)

1. Collagen: Molecular biology, diseases, and potentials for gene therapy
2. Protein motifs. The triple-helix motif in proteins
3. The zipper-like folding of collagen triple helices and the effects of mutations that disrupt the zipper
4. Osteogenesis Imperfecta
5. Genetic heterogeneity in Osteogenesis Imperfecta I
6. Heterogeneity of Osteogenesis Imperfecta type I
7. Classification of Osteogenesis Imperfecta by dental characteristics
8. Osteogenesis Imperfecta and hearing loss
9. Perinatal lethal Osteogenesis Imperfecta (OI Type II): A biochemically heterogeneous disorder usually due to new mutations in the genes for type I collagen
10. 'Popcorn' ossifications: A prognostic sign in Osteogenesis Imperfecta
11. Osteogenesis Imperfecta
12. Evaluation of growth hormone axis and responsiveness to growth stimulation of short children with Osteogenesis Imperfecta
13. Type V Osteogenesis Imperfecta
14. Osteogenesis Imperfecta Type I: Molecular heterogeneity for COL1A1 null alleles of type I collagen
15. Mutations in fibrillar collagens (Type I, II, III and XI), fibril-associated collagen (Type IX) and network-forming collagen (Type X) cause a spectrum of disease of bone, cartilage, and blood vessels
16. Folding of collagen triple helices and the effects of mutations that disrupt the zipper
17. The molecular genetics of collagen
18. Distinct biochemical phenotypes predict clinical severity in non-lethal variants of osteogeneisis imperfecta
19. Osteogenesis Imperfecta: Translation of mutations to phenotype
20. Serine for glycine substitution in type I collagen in two cases of type IV Osteogenesis Imperfecta (OI): Additional evidence for a regional model of OI pathophysiology
21. Perinatal lethal Osteogenesis Imperfecta in transgenic mice bearing an engineered mutant proα1(I) collagen gene
22. Transgenic mice that express a mini-gene version of the human gene for type I procollagen (COL1A1) develop a phenotype resembling a lethal form of Osteogenesis Imperfecta
23. Defective proα2(I) collagen synthesis in a recessive mutation in mice: A model of human Osteogenesis Imperfecta
24. Embryonic lethal mutation in mice induced by retrovirus insertion into the α1(I) collagen gene
25. Transgenic mouse model of the mild dominant form of Osteogenesis Imperfecta
26. Use of the Cre/lox recombination system to develop a non-lethal knock-in murine model for Osteogenesis Imperfecta with an α1(I) G 349C substitution. Variability in phenotype in BrtlIV mice
27. Three novel type I collagen mutations in Osteogenesis Imperfecta type IV probands are associated with discrepancies between electrophoretic migration in osteoblast and fibroblast collagen
28. Manipulation of transgenes by site-specific recombination: Use of Cre recombinase
29. Gene therapy for genetic diseases
30. Ribozymes: Structure, function and potential therapy for dominant genetic disorders
31. Partial rescue of a lethal phenotype of fragile bones in transgenic mice with a chimeric antisense gene directed against a mutated collagen gene
32. Specific inhibition of expression of a human collagen gene (COL1A1) with modified antisense oligonucleotides. The most effective target sites are clustered in double-stranded regions of the predicted secondary structure for the mRNA
33. Antisense oligodeoxynucleotydes selectively suppress expression of the mutant α2(I) collagen allele in type IV Osteogenesis Imperfecta fibroblasts. A molecular approach to therapeutics of dominant negative disorders
34. Cleavage of collagen RNA transcripts by hammerhead ribozymes in vitro is mutation-specific and shows competitive binding effects
35. A mutation-independent therapeutic strategem for Osteogenesis Imperfecta
36. Parental mosaicism and autosomal dominant mutations causing structural abnormalities of collagen type I are frequent in families with Osteogenesis Imperfecta
37. Genetic Counselling on brittle grounds: Recurring Osteogenesis Imperfecta due to parental mosaicism for a dominant mutation
38. Somatic cell mosaicism another source of phenotypic heterogeneity in nuclear families with Osteogenesis Imperfecta
39. Marrow stromal cells as stem cells for nonhematopoietic tissues
40. Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice
41. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with Osteogenesis Imperfecta